Explore the Global Targeted RNAi Molecule Platform Market— analysis of key trends, regional growth, top players, and a 10-year forecast from 2026 to 2036.

Future Market Insights

Targeted RNAi Molecule Platform Market

Key Insight

GalNAc-conjugated siRNA leads the platform technology category with 33.4% share in 2026, while hepatic targets account for 33.0% of target type share. Cardiometabolic diseases hold 30.4% of application share, supported by established liver delivery, measurable endpoints, durable gene silencing, and broader clinical development.

August 01, 2026

Anurag Sharma

250 Pages

Cite this Report

Targeted RNAi Molecule Platform Market

https://www.futuremarketinsights.com/reports/targeted-rnai-molecule-platform-market

License

Starting at US$ 5000

Buy Now

Summary ToC Infographics Companies

Key Players

Alnylam Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc.
Silence Therapeutics plc
Dicerna Pharmaceuticals (Novo Nordisk)
OliX Pharmaceuticals, Inc.
Sirnaomics Ltd.

Methodology

Member of

Greater New York Chamber of Commerce

Recognized by

Awarded by

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

BRONZE STEVIE® Award

20th annual IBAs

Quick Contact

Chat on Whatsapp + 44 20 3769 9709 + 1 347 918 3531 Contact By Email

Get Free Sample PDF

Targeted RNAi Molecule Platform Market

Key Players

Similar Industry Reports